Commentary: **Challenges and Pathways for Clinical and Translational Research: Why Is This Research Different From All Other Research?**

Harold Alan Pincus, MD

**Abstract**

Three related articles in this issue addressing clinical and translational (C/T) research suggest four simple questions about such research that should be considered by policy makers at a national level, by academic institutions, and by individual scientists: What, who, how, and why. The author of this commentary posits that ambiguity in answering these questions means that policy makers are not providing a clear target for institutions and researchers. The vagueness of the definitions may also obscure accountability with regard to assessing whether the rhetoric matches actions—for instance, what is the distribution of research activities and funding across the different phases of C/T research? Given the rapid evolution of new tools and methodologies in C/T research, it is important to consider each of these issues across the full developmental pathway of a C/T researcher. Overcoming these challenges and rapidly advancing along the pathway of creating knowledge to enhance the health of our communities and the nation depends on coherence and agreement by all players involved in C/T policy, funding, and participation.

Acad Med. 2009; 84:000–000.

**Editor’s Notes:** Due to an error that occurred during production, an incorrect version of Pincus HA. Commentary: Challenges and pathways for clinical and translational research: Why is this research different from all other research? Acad Med. 2009;84:411–412 was printed. The incorrect version omits some of the text. The correct version appears here in its entirety.


At the Passover Seder, Jewish tradition obligates all participants to ask and respond to four questions regarding the unique attributes of the holiday. Although typically recited by the youngest (and, thus, most naïve) child at the table, these questions are intended to be a focus of serious discussion and thought for the broader community, the family, and the individual because they represent important, larger issues.

In a similar manner, the articles in this issue relating to clinical and translational (C/T) research suggest four simple, yet profound questions regarding such research that should be considered by policy makers at a national level, by academic institutions, and by individual scientists: What, who, how, and why.

**What is C/T research?** Each of the three articles related to this commentary focus on a somewhat different part of the elephant. Heller and de Melo-Martín note the two types of “translational research” defined in the National Institutes of Health (NIH) Clinical and Translational Science Awards (CTSA) Request for Application: (a) Applying basic discoveries to clinical applications and (b) enhancing adoption of best practices in the community. However, they focus their attention primarily on barriers to (a). For his historical analysis of clinical research training, Teo applies the official NIH definition of “clinical research”: “Patient oriented research, epidemiological and behavioral studies, and health services research.” A significant portion of this article examines training programs that seem to be more closely linked to (b)—that is, those that offer an MPH degree or that focus on health services and quality research, such as the Robert Wood Johnson Foundation Clinical Scholars Program and the Harvard Program in Clinical Effectiveness (also described by Goldhamer et al.). Moreover, multiple other commentators have suggested alternative models of C/T research (e.g., Woolf and Dougherty and Conway, among others) and the CTSA Consortium Evaluation Key Function Committee is also developing a framework for defining C/T research.

The problem with all this ambiguity is that policy makers are not providing a clear target for institutions and researchers. The vagueness of the definitions may also obscure accountability with regard to assessing whether the rhetoric matches actions—for instance, what is the distribution of research activities and funding across the different phases of C/T research?—(a) versus (b), T1 versus T2 versus T3, and so forth. To what extent do the currently popular concepts of C/T research and comparative effectiveness overlap?

**Who will be the future C/T researchers?** Critical to answering this question are issues of recruitment, training, mentoring (and menteeing), social supports, the institutional reward system, and the
impact of federal and other programs. Heller and de Melo-Martín’s first-listed set of barriers and solutions are training and mentoring. Teo, as well as Goldhamer and colleagues, focus on training primarily at the fellowship level and also note the importance of mentorship. However, given the rapid evolution of new tools and methodologies in C/T research, it is important to consider each of these issues across the full developmental pathway of a C/T researcher—that is, from undergraduate experience (or, perhaps, even birth) to retirement.

Moreover, as Heller and de Melo-Martín note, academic rewards and incentives are generally not under the control of CTSAs but require leadership and action at higher institutional levels. In a recent article, Keyser et al. suggest how such leadership can be exercised and assessed with regard to research mentorship. In addition, just as a clearer notion of the “what” is needed, there also should be a clear set of expectations for the “who.” An overarching description of the roles/tasks of a C/T researcher, adapted from an article by Burke et al. is suggested in List 1, and a more detailed set of C/T research competencies is being developed by the CTSA Consortium Education Key Function Committee.

How are we going to overcome these challenges and rapidly advance along the pathway of creating knowledge to enhance the health of our communities and the nation? It is also worth noting some of the multiple “subquestions” that are embedded in this complex question: Where should C/T research activities take place? (It can’t be just the CTSAs.) How can the practical and regulatory barriers be overcome (and still maintain oversight, accountability, and adherence to the highest ethical standards)? How much funding will be needed (and where will it come from)? How can we best evaluate these strategies (and change them if expectations are not being met)?

Obviously, answering these questions is well beyond the space and scope of this commentary. Nonetheless, there are forces gathering and forums developing that call on us to address these issues. A new scientific organization, the Society for Clinical and Translational Science, has been formed as a forum for focusing both scientific and policy attention on C/T research. National professional associations, (e.g., the Association of American Medical Colleges, the Association of Professors of Medicine’s Physician–Scientist Initiative) have focused on the leaky pipeline of C/T researchers. The NIH has designed the CTSA program to incorporate strategies at multiple levels: Within their institutions, across their community, and as a consortium across the nation. In this latter capacity the CTSA consortium has established specific strategic goals to align their efforts in ways that will respond to these policy issues. As of this writing, the federal government is implementing legislation proposed by the Obama administration and passed by Congress in the context of the stimulus package that will augment resources for C/T research. Finally, it is quite clear that the coming debate on health care reform will involve substantial discussion of how we can enhance and harness science in the service of improving the performance of our health system.

There is, of course, a fourth question: Why is this research different from all other research? Fortunately, the answer is simple and perhaps can be summed up by paraphrasing Bill Clinton’s Presidential Campaign War Room: “It’s the patient, stupid!”

Acknowledgments
The author acknowledges the general support of: the John A. Hartford Foundation/RAND program on Building Interdisciplinary Geriatric Research Centers; Irving Institute for Clinical and Translational Research at Columbia University funded by the National Center for Research Resources (UL1RR024155); University of Pittsburgh Clinical and Translational Science Institute funded by NCRR (UL1RR024153); Mental Health Therapeutics CERT at Rutgers; and the State University of New Jersey funded by the Agency for Health Care Research and Quality (SU1HS016097), Columbia subcontract.

References